IRAK4 and acute myeloid leukemia: A small molecule dual inhibitor of FLT3/IRAK4 can overcome adaptive resistance in FLT3-ITD AML preclinical models by inhibiting compensatory IRAK 1/4 activation and downstream immune activation in FLT3-ITD AML [30].